About Paul Diaz
At the 2022 National Society of Genetic Counselors (NSGC) annual conference, Paul J. Diaz, president and CEO of Myriad Genetics, described the company's focus on three pillars: evolving products by expanding gene panels and adding risk scores for patients of all ancestry; operationalizing science in practice through workflow and ease of use; and making genetics accessible through direct pay options, financial assistance, and price transparency. Diaz stated that the role of genetic counselors is "integral to our mission" and that he spent time at the conference "learning and taking it all in and thinking about ways that we can be better partners." He also said Myriad Genetics is "excited to partner with NSGC on everything from workflow to education to clinics."
At the 2022 ASCO meeting, Diaz discussed the company's precise oncology solutions, saying the goal is to "make our science more approachable, make it easier to use and really bring the benefit of those high quality tests together in one easy to use report." He noted that partnerships with Illumina and Intermountain allow the companies to "get to market faster" and "do it in a more efficient way which brings down the cost," which he said makes genetic testing more accessible. Diaz described Myriad Genetics' mission as helping physicians "detect, treat disease and help manage disease" while putting "patients in the center of that."
Source: AI-verified profile updated from Paul Diaz's recent appearances.
Browse all interviews →
Transcript (3 segments)
P
Paul Diaz0:00
It's really exciting to be here, and it's been a really energizing couple of days. Myriad Genetics has been a leader in precision medicine and genetic testing for over 31 years. Physicians are taking care of many patients during the course of the day, and our job is to bring the science and make it easier for them so they can engage with their patients in a different way. So, precise oncology solutions really embodies what we're trying to do, which is make our science more approachable, make it easier to use, and really bring the benefit of those high-quality tests together in one easy-to-use report.
If our healthcare system is really going to come out of the pandemic and change the way we do things, speed matters. And we found with Illumina and Intermountain great partners that if everyone does what they're best at, we can get to market faster, we can do it in a more efficient way which brings down the cost, and if you bring down the cost you make genetic testing and insights more accessible. So it really was about bringing the capabilities of the three companies together to bring precise oncology solutions to market in a more efficient way, and that benefits our patients, our teammates, our physician partners, and our shareholders.
Our mission is to help physicians and other providers detect, treat, and help manage disease. And increasingly every day, I think we're putting patients at the center of that and improving their engagement in their own health, and that's what we're really excited about and gets us up every morning.
